tirzepatide latest news https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound FDA approves weight-loss drug Zepbound

A study utilizing a national database found that individuals treated with GLP-1 receptor agonists had a significantly lower risk of developing glaucoma compared to those who were not on these medications

De estos, cinco estudios (SUSTAIN 1-5) el objetivo principal fue la evaluacin de la eficacia glucmica, mientras que un estudio (SUSTAIN 6) tuvo como objetivo primario evaluar el resultado en desenlaces cardiovasculares

Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes2022

Originally prescribed to treat diabetes, these meds really entered the zeitgeist for their notable weight loss side effects

The choice of treatment depends on individual health status, the severity of diabetes, and any other pregnancy-related factors

This action helps reduce localized fat pockets and supports smoother, more even skin texture after treatment